DBV Technologies SA

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

27 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

16 Oct 2023 02:00:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023

05 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

05 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

31 Jul 2023 16:25:00 By Nasdaq GlobeNewswire

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

25 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023

19 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

10 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023

16 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming EAACI Congress 2023

08 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

06 Jun 2023 17:00:00 By Nasdaq GlobeNewswire

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

10 May 2023 17:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

09 May 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Reports First Quarter 2023 Financial Results

04 May 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

19 Apr 2023 17:09:21 By Nasdaq GlobeNewswire

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

12 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

Ordinary and Extraordinary General Meeting of April 12, 2023

24 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Update

13 Mar 2023 01:30:00 By Nasdaq GlobeNewswire

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

07 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

02 Mar 2023 17:30:00 By Nasdaq GlobeNewswire